Immuron receives US funding to develop gut treatment
ASX-listed gut health company Immuron has been awarded a $5.5 million grant by the US Department of Defence to develop an anti-microbial oral drug targeting diarrhoea-causing bacteria for military and traveller use.
Also @AuManufacturing